BRIEF published on 08/01/2024 at 14:10, 2 years 1 month ago EnVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update Financial Results FDA Approval Corporate Update Venous Disease VenoValve Trial
BRIEF published on 08/01/2024 at 14:10, 2 years 1 month ago EnVVeno Medical publie ses résultats financiers du deuxième trimestre 2024 et fait le point sur son entreprise Résultats Financiers Mise À Jour De L'entreprise Approbation De La FDA Maladie Veineuse Essai VenoValve
BRIEF published on 08/01/2024 at 14:05, 2 years 1 month ago Bold Ventures Completes Initial Tranche of Non-Brokered Private Placement Private Placement Mining Investments Exploration Funding Bold Ventures Initial Tranche
BRIEF published on 08/01/2024 at 14:05, 2 years 1 month ago Bold Ventures finalise la tranche initiale d'un placement privé sans intermédiaire Placement Privé Investissements Miniers Financement De L'exploration Des Entreprises Audacieuses Tranche Initiale
BRIEF published on 08/01/2024 at 13:55, 2 years 1 month ago Polaris Renewable Energy Reports Q2 2024 Results Financial Performance Sustainability Strategy Energy Production Polaris Renewable Energy Q2 2024 Results
BRIEF published on 08/01/2024 at 13:55, 2 years 1 month ago Polaris Renewable Energy publie ses résultats du deuxième trimestre 2024 Performance Financière Production D'énergie Énergie Renouvelable Polaris Résultats Du Deuxième Trimestre 2024 Stratégie De Durabilité
BRIEF published on 08/01/2024 at 13:55, 2 years 1 month ago Braille Energy Systems Announces Non-Brokered Private Placement Private Placement Financing TSX Venture Accredited Investors Braille Energy
BRIEF published on 08/01/2024 at 13:55, 2 years 1 month ago Braille Energy Systems annonce un placement privé sans intermédiaire Financement Placement Privé Bourse De Croissance TSX Investisseurs Qualifiés Énergie Braille
BRIEF published on 08/01/2024 at 13:45, 2 years 1 month ago Cairn Homes Plc: Total Voting Rights Update Ordinary Shares Cairn Homes Plc Total Voting Rights Regulatory Announcement Transparency Directive
BRIEF published on 08/01/2024 at 13:45, 2 years 1 month ago Cairn Homes Plc : mise à jour du total des droits de vote Cairn Homes Actions Ordinaires Droits De Vote Totaux Annonce Réglementaire Directive Sur La Transparence
Published on 09/11/2026 at 17:00, 3 hours 38 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 3 hours 38 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 5 hours 13 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 5 hours 38 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 6 hours 8 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 19:44, 53 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 2 hours 23 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 2 hours 38 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 13 hours 38 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 13 hours 38 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 13 hours 38 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 13 hours 38 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
